Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.
The Journal of pharmacology and experimental therapeutics October 18, 2024 Rachel Luba, Gabriela Madera, Rebecca Schusterman et al. 2 citations
Lenabasum, a selective CB2 receptor agonist, was tested for abuse potential in 56 people who use cannabis recreationally. At the target therapeutic dose of 20 mg, lenabasum did not increase ratings of drug liking compared with placebo. However, higher, supratherapeutic doses of 60 and 120 mg did produce dose-dependent increases in drug liking, though less than nabilone, an FDA-approved medication. Lenabasum was safe and well tolerated, but it does have abuse potential and should be used cautiously in clinical settings.